OncoMatch

OncoMatch/Clinical Trials/NCT06620848

A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.

Is NCT06620848 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including HRS-4642 monotherapy and HRS-4642 and adebrelimab combination therapy for biliary tract cancer.

Phase 2RecruitingShanghai Zhongshan HospitalNCT06620848Data as of Jun 2026Location: China

Treatment: HRS-4642 monotherapy · HRS-4642 and adebrelimab combination therapyThe study was designed to evaluate the efficacy and safety of HRS-4642 monotherapy or in combination with adebrelimab in the treatment of advanced biliary tract tumor patients.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

HRS-4642 monotherapyHRS-4642 and adebrelimab combination therapy

Cancer type

Cholangiocarcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75

Prior therapy

Min 1 prior line

Must have received: systemic therapy

progression or intolerance for  one line of systemic therapy

Must have received: gemcitabine-based chemotherapy (gemcitabine) — adjuvant or neoadjuvant

adjuvant therapy or neoadjuvant therapy must include gemcitabine-based chemotherapy

Cannot have received: anti-tumor chemotherapy

Exception: within 4 weeks before the study drug administration

Prior anti-tumor chemotherapy within 4 weeks before the study drug administration

Cannot have received: small molecular targeted drugs

Exception: with a half-life of less than 5 or 7 days from the first medication

Small molecular targeted drugs (including oral targeted drugs for other clinical trials) with a half-life of less than 5 or 7 days from the first medication

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06620848 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior anti-tumor chemotherapy, small molecular targeted drugs disqualifies patients from enrollment.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify